Medical - Care Facilities
Compare Stocks
2 / 10Stock Comparison
MNDR vs DOCS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
MNDR vs DOCS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Care Facilities | Medical - Healthcare Information Services |
| Market Cap | $342K | $5.24B |
| Revenue (TTM) | $21M | $638M |
| Net Income (TTM) | $-16M | $239M |
| Gross Margin | 2.0% | 89.7% |
| Operating Margin | -73.8% | 37.4% |
| Forward P/E | — | 16.8x |
| Total Debt | $244K | $12M |
| Cash & Equiv. | $812K | $210M |
MNDR vs DOCS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 24 | May 26 | Return |
|---|---|---|---|
| Mobile-health Netwo… (MNDR) | 100 | 0.1 | -99.9% |
| Doximity, Inc. (DOCS) | 100 | 107.2 | +7.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MNDR vs DOCS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
In this particular matchup, MNDR is outpaced on most metrics by others in the set.
DOCS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 20.0%, EPS growth 54.2%, 3Y rev CAGR 18.4%
- -50.9% 10Y total return vs MNDR's -99.6%
- Lower volatility, beta 1.03, Low D/E 1.1%, current ratio 6.97x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.0% revenue growth vs MNDR's -58.7% | |
| Quality / Margins | 37.5% margin vs MNDR's -73.1% | |
| Stability / Safety | Lower D/E ratio (1.1% vs 11.9%) | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -55.4% vs MNDR's -82.9% | |
| Efficiency (ROA) | 20.7% ROA vs MNDR's -361.4% |
MNDR vs DOCS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
MNDR vs DOCS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DOCS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
DOCS is the larger business by revenue, generating $638M annually — 30.0x MNDR's $21M. DOCS is the more profitable business, keeping 37.5% of every revenue dollar as net income compared to MNDR's -73.1%. On growth, DOCS holds the edge at +9.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $21M | $638M |
| EBITDAEarnings before interest/tax | -$15M | $250M |
| Net IncomeAfter-tax profit | -$16M | $239M |
| Free Cash FlowCash after capex | -$8M | $314M |
| Gross MarginGross profit ÷ Revenue | +2.0% | +89.7% |
| Operating MarginEBIT ÷ Revenue | -73.8% | +37.4% |
| Net MarginNet income ÷ Revenue | -73.1% | +37.5% |
| FCF MarginFCF ÷ Revenue | -38.4% | +49.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -35.6% | +9.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +15.6% | -16.2% |
Valuation Metrics
MNDR leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $341,509 | $5.2B |
| Enterprise ValueMkt cap + debt − cash | -$226,539 | $5.0B |
| Trailing P/EPrice ÷ TTM EPS | -0.08x | 23.45x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 16.83x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.30x |
| EV / EBITDAEnterprise value multiple | — | 21.14x |
| Price / SalesMarket cap ÷ Revenue | 0.06x | 9.18x |
| Price / BookPrice ÷ Book value/share | 0.10x | 4.84x |
| Price / FCFMarket cap ÷ FCF | — | 19.64x |
Profitability & Efficiency
DOCS leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
DOCS delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-6 for MNDR. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to MNDR's 0.12x. On the Piotroski fundamental quality scale (0–9), DOCS scores 9/9 vs MNDR's 2/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -6.1% | +24.4% |
| ROA (TTM)Return on assets | -3.6% | +20.7% |
| ROICReturn on invested capital | — | +20.0% |
| ROCEReturn on capital employed | -76.9% | +22.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 9 |
| Debt / EquityFinancial leverage | 0.12x | 0.01x |
| Net DebtTotal debt minus cash | -$568,048 | -$197M |
| Cash & Equiv.Liquid assets | $811,920 | $210M |
| Total DebtShort + long-term debt | $243,872 | $12M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (Dividends Reinvested)
DOCS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DOCS five years ago would be worth $4,911 today (with dividends reinvested), compared to $44 for MNDR. Over the past 12 months, DOCS leads with a -55.4% total return vs MNDR's -82.9%. The 3-year compound annual growth rate (CAGR) favors DOCS at -8.8% vs MNDR's -83.7% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +23.2% | -39.9% |
| 1-Year ReturnPast 12 months | -82.9% | -55.4% |
| 3-Year ReturnCumulative with dividends | -99.6% | -24.2% |
| 5-Year ReturnCumulative with dividends | -99.6% | -50.9% |
| 10-Year ReturnCumulative with dividends | -99.6% | -50.9% |
| CAGR (3Y)Annualised 3-year return | -83.7% | -8.8% |
Risk & Volatility
Evenly matched — MNDR and DOCS each lead in 1 of 2 comparable metrics.
Risk & Volatility
MNDR is the less volatile stock with a -0.25 beta — it tends to amplify market swings less than DOCS's 1.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DOCS currently trades 34.0% from its 52-week high vs MNDR's 14.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.25x | 1.03x |
| 52-Week HighHighest price in past year | $7.95 | $76.51 |
| 52-Week LowLowest price in past year | $0.66 | $20.55 |
| % of 52W HighCurrent price vs 52-week peak | +14.7% | +34.0% |
| RSI (14)Momentum oscillator 0–100 | 68.9 | 60.1 |
| Avg Volume (50D)Average daily shares traded | 3.1M | 2.7M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $42.79 |
| # AnalystsCovering analysts | — | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.3% |
DOCS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MNDR leads in 1 (Valuation Metrics). 1 tied.
MNDR vs DOCS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MNDR or DOCS a better buy right now?
For growth investors, Doximity, Inc.
(DOCS) is the stronger pick with 20. 0% revenue growth year-over-year, versus -58. 7% for Mobile-health Network Solutions Class A Ordinary Shares (MNDR). Doximity, Inc. (DOCS) offers the better valuation at 23. 5x trailing P/E (16. 8x forward), making it the more compelling value choice. Analysts rate Doximity, Inc. (DOCS) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MNDR or DOCS?
Over the past 5 years, Doximity, Inc.
(DOCS) delivered a total return of -50. 9%, compared to -99. 6% for Mobile-health Network Solutions Class A Ordinary Shares (MNDR). Over 10 years, the gap is even starker: DOCS returned -50. 9% versus MNDR's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MNDR or DOCS?
By beta (market sensitivity over 5 years), Mobile-health Network Solutions Class A Ordinary Shares (MNDR) is the lower-risk stock at -0.
25β versus Doximity, Inc. 's 1. 03β — meaning DOCS is approximately -519% more volatile than MNDR relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 12% for Mobile-health Network Solutions Class A Ordinary Shares — giving it more financial flexibility in a downturn.
04Which is growing faster — MNDR or DOCS?
By revenue growth (latest reported year), Doximity, Inc.
(DOCS) is pulling ahead at 20. 0% versus -58. 7% for Mobile-health Network Solutions Class A Ordinary Shares (MNDR). On earnings-per-share growth, the picture is similar: Doximity, Inc. grew EPS 54. 2% year-over-year, compared to 35. 8% for Mobile-health Network Solutions Class A Ordinary Shares. Over a 3-year CAGR, DOCS leads at 18. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MNDR or DOCS?
Doximity, Inc.
(DOCS) is the more profitable company, earning 39. 1% net margin versus -44. 3% for Mobile-health Network Solutions Class A Ordinary Shares — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus -46. 4% for MNDR. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MNDR or DOCS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MNDR or DOCS better for a retirement portfolio?
For long-horizon retirement investors, Mobile-health Network Solutions Class A Ordinary Shares (MNDR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
25)). Both have compounded well over 10 years (MNDR: -99. 6%, DOCS: -50. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MNDR and DOCS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MNDR is a small-cap quality compounder stock; DOCS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.